Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Friday, 21 April 2017

Novo Nordisk A/S - Reduction of the share capital

Novo Nordisk A/S    

Published: 16:28 CEST 21-04-2017 /GlobeNewswire /Source: Novo Nordisk A/S / : NOVO B /ISIN: DK0060534915

Novo Nordisk A/S - Reduction of the share capital

Bagsværd, Denmark, 21 April 2017 - At Novo Nordisk's Annual General Meeting on 23 March 2017, it was decided to reduce the company's B share capital from DKK 402,512,800 to DKK 392,512,800 by cancellation of part of the company's portfolio of own B shares at a nominal value of DKK 10,000,000 divided into 50,000,000 B shares of DKK 0.20 each. 

Today, Novo Nordisk has registered the implementation of the reduction of the share capital with the Danish Business Authority and cancelled nominally DKK 10,000,000 B shares. After the reduction of the share capital, the company's share capital is nominally DKK 500,000,000, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 392,512,800.

 

The reduction in the share capital will not affect Novo Nordisk's share repurchase programme which will continue as previously announced.

 

Further information

Media:

 

 

Anne Margrethe Hauge

+45 3079 3450

amhg@novonordisk.com

 

Investors:

 

 

Peter Hugreffe Ankersen

+45 3075 9085

phak@novonordisk.com

Hanna Ögren

Anders Mikkelsen

Kasper Veje (US)

+45 3079 8519

+45 3079 4461

+1 609 235 8567

haoe@novonordisk.com

armk@novonordisk.com

kpvj@novonordisk.com


Company announcement No 29 / 2017 




CA170421_Kapitalnedsættelse_UK



This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Novo Nordisk A/S, Novo Allé, Bagsvaerd DK-2880, Denmark
If you would like to unsubscribe and stop receiving these e-mails click here.